Novo Nordisk A/S (LTS:0QIU) Ending Cash Position : kr14,392 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Novo Nordisk A/S Ending Cash Position?

Novo Nordisk A/S's Ending Cash Position for the quarter that ended in Dec. 2023 was kr14,392 Mil.

Novo Nordisk A/S's quarterly Ending Cash Position increased from Jun. 2023 (kr21,574 Mil) to Sep. 2023 (kr29,883 Mil) but then declined from Sep. 2023 (kr29,883 Mil) to Dec. 2023 (kr14,392 Mil).

Novo Nordisk A/S's annual Ending Cash Position increased from Dec. 2021 (kr10,719 Mil) to Dec. 2022 (kr12,653 Mil) and increased from Dec. 2022 (kr12,653 Mil) to Dec. 2023 (kr14,392 Mil).

Novo Nordisk A/S Ending Cash Position Historical Data

The historical data trend for Novo Nordisk A/S's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Ending Cash Position Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

15,411.00

12,226.00

10,719.00

12,653.00

14,392.00

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															12,653.00	14,936.00	21,574.00	29,883.00	14,392.00

Novo Nordisk A/S Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Novo Nordisk A/S's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	12653	+	1739
	=	14,392

Novo Nordisk A/S's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	29883	+	-15491
	=	14,392

Novo Nordisk A/S Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (LTS:0QIU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (LTS:0QIU) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (LTS:0QIU) Headlines

No Headlines